FDA approves Immgolis as first golimumab biosimilar for ulcerative colitis, RA

The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis. Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a biosimilar to golimumab (Simponi, Johnson & Johnson) for adults with moderately to severely active ulcerative colitis. It is administered via subcutaneous injection in a single-dose prefilled syringe.